Chiron's manufacturing misfortunes boost competitors

Article Abstract:

Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California's company's future ability to compete in this particular segment of the vaccine market. Chiron had to scrap all 12 million doses of Begrivac influenza vaccine scheduled to come out of its Marburg plant in Germany in July 2005, due to the product's sterility problems and has thus made hard for Chiron to maintain its position as the world's second largest flu vaccine supplier.

Market share, Chiron Corp., CHIR, Company market share, Viral vaccines

---

The business of making vaccines

Article Abstract:

Traditional vaccine companies are responding to the growing need for better and more plentiful vaccines by increasing manufacturing capacity either through acquisitions or through building facilities from the start. The domination of the larger industry players is being challenged from below by innovative biotechnology companies working on creating new and more robust delivery systems, as well as from within their own peer group.

Production management, Capacity, Biotechnology industry, Biotechnology industries, Vaccines

---

Diversa restructures, raining question over bioprospecting

Article Abstract:

Diversa of San Diego, California, is planning to restructure in 2006, thereby raising questions about scientific research in the fields of bioprospecting and industrial biotech. The main aim for restructuring is both to conserve its cash pile and to concentrate on building up products sales more rapidly than it has managed earlier.

Organizational history, Management dynamics, Management, Company restructuring/company reorganization, Reorganization and restructuring, Company business management, Company organization, Diversa Corp.

Similar abstracts:

• Abstracts: WMD: Big money, big controversy. Lawmakers raise questions about Marine One, other helo programs. Continued supplementals will be key for Army, Sullivan says
• Abstracts: Performance pricing in bank debt contracts. Discussion of the effects of corporate governance on firms' credit ratings
• Abstracts: Synthetic gene firms evolve toward sustainable business? The past, present, and future of biotechnology in Mexico
• Abstracts: Digging for justice. Digging deep. Value judgments
• Abstracts: Stem cell therapy for MS? Stem cell research: a real breakthrough. The silent killer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.